MK-8141: renin inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11578126 |
| CHEMBL ID | 1230745 |
| SCHEMBL ID | 1472318 |
| MeSH ID | M0553184 |
| Synonym |
|---|
| act-077825 |
| CHEMBL1230745 , |
| (1r,5s)-n-cyclopropyl-7-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-n-(2,3-dimethylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide |
| bdbm50330355 |
| (1r,5s)-n-cyclopropyl-7-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-n-(2,3-dimethylbenzyl)-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide |
| SCHEMBL1472318 |
| mk-8141 |
| 3,9-diazabicyclo(3.3.1)non-6-ene-6-carboxamide, n-cyclopropyl-7-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-n-((2,3-dimethylphenyl)methyl)-, (1r,5s)- |
| VKBBVOVNGWGZCA-HVIPQOSHSA-N |
| (rac.)-(1r*,5s*)-7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide |
| Q27276673 |
| (1r,5s)-n-cyclopropyl-7-[4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl]-n-[(2,3-dimethylphenyl)methyl]-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxamide |
| AKOS040746122 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " ACT-077825 pharmacokinetics on days 1 and 7 were characterized by dose-proportional increases in Cmax and AUCτ." | ( Pharmacokinetics, pharmacodynamics, and tolerability of ACT-077825, a new direct renin inhibitor after multiple-ascending doses in healthy subjects. Binkert, C; Dingemanse, J; Gutierrez, M; Nicolas, LB, 2013) | 0.39 |
| "Upon pooling male and female subjects, exposure was higher in elderly compared to young subjects, showing an increase of 65% for AUC0-∞, 40% for Cmax and 38% for t1/2." | ( Single-dose pharmacokinetics of the renin inhibitor ACT-077825 in elderly and young subjects of both sexes. Cavallaro, M; Dingemanse, J; Eydeler, U, 2014) | 0.4 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results provide evidence that ACT-077825, with a pharmacokinetic profile consistent with a once-a-day dosing regimen, may represent an effective antihypertensive agent and pave the way toward a multiple-ascending dose study." | ( Entry-into-humans study with a new direct renin inhibitor. Binkert, C; Dingemanse, J; Gutierrez, MM; Nicolas, LB, 2012) | 0.38 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Renin | Homo sapiens (human) | IC50 (µMol) | 0.0002 | 0.0000 | 0.7796 | 8.2000 | AID537696 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 (µMol) | 0.0002 | 0.0002 | 1.5574 | 10.0000 | AID537696 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| aspartic-type endopeptidase activity | Renin | Homo sapiens (human) |
| signaling receptor binding | Renin | Homo sapiens (human) |
| insulin-like growth factor receptor binding | Renin | Homo sapiens (human) |
| protein binding | Renin | Homo sapiens (human) |
| peptidase activity | Renin | Homo sapiens (human) |
| peroxidase activity | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| prostaglandin-endoperoxide synthase activity | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| protein binding | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| heme binding | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| metal ion binding | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Renin | Homo sapiens (human) |
| extracellular space | Renin | Homo sapiens (human) |
| plasma membrane | Renin | Homo sapiens (human) |
| apical part of cell | Renin | Homo sapiens (human) |
| extracellular space | Renin | Homo sapiens (human) |
| photoreceptor outer segment | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| cytoplasm | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| Golgi apparatus | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| extracellular exosome | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| cytoplasm | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| neuron projection | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID537714 | Oral bioavailability in Wistar rat | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537707 | Plasma protein binding in monkey | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537702 | Oral bioavailability in rat | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537705 | Plasma protein binding in human | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537695 | Inhibition of renin in plasma | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537706 | Plasma protein binding in dog | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537700 | Distribution coefficient, log D of the compound | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537696 | Inhibition of human recombinant renin in buffer | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537716 | Elimination half life in Wistar rat | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| AID537719 | Tmax in Wistar rat | 2010 | Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21 | Direct renin inhibitors as a new therapy for hypertension. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (60.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1 (20.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||